Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
NCT07469800 on ClinicalTrials.gov · last registry update 2026-05-27
Recruiting now, toward 336 participants. Its estimated completion date, 1 August 2026, has passed with no update to the record. Primary outcome, as filed: To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 336
- Started
- 2026-04-23
- Primary completion
- 2026-08-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment.
Conditions studied
Overweight · Obesity · Hypertensive
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.